{
    "nctId": "NCT01669343",
    "briefTitle": "Aromatase Inhibitor Host Factors Study",
    "officialTitle": "Patient-related Predictors of Estrogen Suppression in Postmenopausal Women Using Adjuvant Letrozole",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 121,
    "primaryOutcomeMeasure": "Part A Correlation of Day 29 Estradiol With BMI",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal female patients\n* histological confirmed diagnosis of estrogen receptor and/or progesterone receptor positive breast cancer (Stage I-III) who have completed local therapy\n* Currently prescribed and taking letrozole 2.5 mg daily for a minimum of 3 months\n* Willing to provide written informed consent to participate\n* for the experimental arm: all of the above and body mass index (BMI) \\> 25 kg/m2\n\nExclusion Criteria:\n\n* Known abnormal liver or renal function defined by:\n\n  1. Serum Creatinine \\> 1.25 times institutional upper limit of normal (ULN) or Calculated Creatinine Clearance \\< 40 mL/min\n  2. Serum Bilirubin, Aspartate transaminase (AST) or alanine transaminase (ALT) \\> 1.5 times ULN\n* Presence of persistent local or known metastatic cancer",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}